Semaglutide 1 mg demonstrated statistically significant and superior improvement in maximum walking distance by 13% over placebo in adults with type 2 diabetes and symptomatic PAD1 Based on STRIDE trial data, presented at the American College of Cardiology's (ACC) Annual Scientific...
Read More Details
Finally We wish PressBee provided you with enough information of ( Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial in adults with type 2 diabetes and peripheral artery disease (PAD) presented at ACC 2025 )
Also on site :
- Ben & Jerry's New Ice Cream Flavor Has Fans Saying the Same Thing
- Iconic '70s Rocker Releases First Album In Nearly a Decade
- 2 healthcare workers accused of elder abuse after woman, 92, found with broken bones